Key result
Dual and triple combination therapy for hypertension provides good clinical outcomes, compliance, and a low profile of side effects, with future trends pointing toward combinations including statins.
Why the study?
Does fixed combination antihypertensive therapy improve clinical outcomes, tolerability, and patient compliance compared to monotherapy in hypertensive patients?
Does fixed combination antihypertensive therapy improve clinical outcomes, tolerability, and patient compliance compared to monotherapy in hypertensive patients?
Fixed-dose combination antihypertensive therapy is recommended to improve patient adherence, enhance blood pressure control, and reduce long-term cardiovascular adverse events.
Answers are grounded in this paper and cite their sources.
May support guideline-recommended combination therapy in high-risk hypertension; leaves open optimal regimens for subgroups.
INTRODUCTION: Hypertension is one of the primary modifiable risk factor for cardiac and renal diseases with the prevalence around 30-45% of the general population, with a steep increase with ageing. The administration of blood pressure-lowering drugs is to reduce the risk of major clinical cardiovascular outcomes. Hypertension guidelines recommend combination therapy in patients with high cardiovascular risk and with subclinical organ damage as well as when monotherapy fails. Areas covered: As the etiology of essential hypertension is multifactorial, combination therapy using different classes of antihypertensive agents have greater effect than each on its own (synergistic effect), may have better tolerability (two components minimizing each other's side effects) and lead to improved patient compliance. Several studies assess the hypotensive efficacy on drug combination; there are also studies on triple drug combination. Expert commentary: At present, dual and triple combination therapy is available to hypertensive patients with good clinical outcomes, compliance and low profile of side effects. It is critical as patients' adherence to the pharmacological therapy significantly decreases the risk of long-term adverse events including mortality. It appears that combinations not only of hypotensive drugs but also with statins (as well as antidiabetics) will be widely used.
No takes yet. Share an insight, caveat, or question.
Łopatowska et al. (2017) conducted a review in Hypertension. Fixed combinations of antihypertensive drugs was evaluated. Dual and triple combination therapy for hypertension provides good clinical outcomes, compliance, and a low profile of side effects, with future trends pointing toward combinations including statins.
Synapse has enriched 10 related papers. Consider them for comparative context: